T-Mobile lifts subscriber forecast amid…
…
TRENDING
The results are in, Genprex (NASDAQ: GNPX) announces positive preclinical lung cancer treatment data
2.6 USD
1.35 USD
0.0899 USD
0.0472 USD
3.77 USD
6.6 USD
0.21 USD
10.84 USD
0.1053 USD
0.0376 USD
0.62 USD
1.71 USD
0.005 USD
0.0577 USD
0.0555 USD
0.9861 USD
0.0249 USD
11.41 USD
0.1897 USD
2.31 USD
The results are in, Genprex (NASDAQ: GNPX) announces positive preclinical lung cancer treatment data Genprex (NASDAQ: GNPX) stock surged 25% after the company announced that its research collaborators will present positive preclinical data on its Reqorsa® Gene Therapy for treating lung cancer at the upcoming 2025 AACR-NCI-EROTC International Conference. The data shows that Reqorsa (quaratusugene ozeplasmid) demonstrated effectiveness against ALK-EML4 …